These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 15917524)

  • 1. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
    Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
    Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
    Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
    Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.
    Vicente E; Villar R; Burguete A; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3321-6. PubMed ID: 18625764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
    Garcia-Contreras L; Sung JC; Muttil P; Padilla D; Telko M; Verberkmoes JL; Elbert KJ; Hickey AJ; Edwards DA
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1436-42. PubMed ID: 20086154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
    Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Shoen C; DeStefano M; Hafkin B; Cynamon M
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):69-73. PubMed ID: 18173880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates.
    Mehta A; Srivastva G; Kachhwaha S; Sharma M; Kothari SL
    J Ethnopharmacol; 2013 Aug; 149(1):195-200. PubMed ID: 23816500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
    Coban AY; Bilgin K; Uzun M; Durupinar B
    Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
    Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
    Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
    Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.